Allarity Therapeutics, Inc. Securities Fraud Lawsuit: A Glimpse into Investor Opportunities

Legal Battle Unfolds

LOS ANGELES, Oct. 17, 2024 /PRNewswire/ — Investors hit by significant losses are now offered a chance to spearhead the securities fraud class action lawsuit against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ALLR.

Key Dates and Details

Class Period: May 17, 2022 – July 19, 2024
Lead Plaintiff Deadline: November 12, 2024

Legal Action Steps

To move into the lead plaintiff position for the Allarity lawsuit, interested parties can provide their contact details at www.glancylaw.com/cases/Allarity-Therapeutics-Inc/. For more details regarding your rights, individuals can contact Charles H. Linehan, of Glancy Prongay & Murray LLP, at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com.

Allegations and Fallout

The complaint asserts that during the Class Period, Allarity failed to disclose crucial details to investors, including allegations of misconduct, regulatory risks, and misleading statements, exposing the Company to potential legal and reputational damage.

Stay Informed

For further updates, follow us on LinkedIn, Twitter, or Facebook.

Legal Counsel and Assistance

To navigate the class action process or gain more insights into the case, contact Charles Linehan, Esquire at Glancy Prongay & Murray LLP. Reach out by phone at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com.

This release may be seen as attorney advertising in specific jurisdictions under the relevant legal and ethical guidelines.